Use cell injection to treat lung tumors or other malignant brain tumors

no image avaiable

An injectable nanoparticle called nanomedicine-ADCN (nanomedicine-ADCN) offers a new and promising approach to treat tumor-forming lung cancer tumors or other malignant brain tumors. To treat these diseases one needs to find new and better ways to target excitable cells with an eye toward improved efficacy. These examples are reviewed in the November 1 2018 online edition of Nature Communications.

Nanomedicine-ADCN is typically injected into the blood of a loved one or into tumors such as knee bladder or prostate to target tumor-forming tumors or for therapy in the patients setting. A nanoparticle bonded with a protein is injected back into the patient which can happen anywhere in the body by clumping together and forms nanomeshield after treatment. This is a fast way of delivering tumor-killing drugs where they are needed most without having to resort to drugs that are available and indicated for specific tumor cancer types.

Nanomedicine-ADCN is not a common ingredient in medical drugs; it is also biocompatible. Those who have smoked it have reported experience but now it is recognized that nanomedicine-ADCN is more bioactive than other formulations. It is also biocompatible and with its morphology can be prepared by throwing it into water. The nanoparticle has a diameter of 100 nanometres and a polar density of 2. 5 parts per billion (ppb) – 11 times lower than those found in vaccine formulations.

Even though nanomedicines are commonly used in medicine they are also being developed for many other applications: for the detection of radiation for electronic displays for light-emitting diodes for wireless communication and hydrogels etc.

In the trial Daisy Lam a former postdoctoral fellow of Raoul Daoust Synthesising Research in Applied Chemistry for Cancer Inc. of Atlanta Georgia noticed that nanomedicine-ADCN was particularly biologically active in irradiated lung cancer cells treated with an antibody against the LT8 antibody which is a tumor receptor implicated in the development of lung cancer. On the other hand tumors treated with other types of cancer cells without LT8 appeared to be less active. It has been postulated that the activation of LT8 is the first step in the development of COVID-19 disease as it is well known that LT8 regulates the development of the lesions that cause COVID-19.

Cryo-EM studies (as well as clinical studies) have revealed that nanomedicine-ADCN is able to kill tumor cell lines without affecting normal cells. So it provides a new form of treatment strategy for treating lung cancers or other malignant brain tumors